Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)
Information source: Abbott
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Arthritis, Juvenile Idiopathic
Intervention: Double-Blind Adalimumab/Placebo + MTX (Biological); Double-Blind Adalimumab/Placebo (Biological); OLE BSA Adalimumab +/- MTX (Drug); OLE FD Adalimumab +/- MTX (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Abbott Official(s) and/or principal investigator(s): Laura Redden, M.D., Ph.D., Study Director, Affiliation: Abbott
Summary
This is a multicenter, Phase 3 randomized, placebo-controlled study designed to evaluate
adalimumab in children 4 to 17 years old with polyarticular juvenile idiopathic arthritis
(JIA) who are either methotrexate (MTX) treated or non-MTX treated.
Clinical Details
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Number of Subjects in the Non-MTX Stratum With Disease Flare During the Double-Blind Phase
Secondary outcome: Number of Subjects Meeting Pediatric American College of Rheumatology 30% (PedACR30) Response Criteria at the End of the Open-Label Lead-In PhaseNumber of Subjects in the MTX Stratum With Disease Flare During the Double-Blind Phase Time to Onset of Disease Flare During the Double-Blind Phase in Subjects in the Non-MTX Stratum Time to Onset of Disease Flare During the Double-Blind Phase in Subjects in the MTX Stratum Number of Subjects Meeting PedACR30 Response Criteria at the End of the Double-Blind Phase Number of Subjects Meeting PedACR50 Response Criteria at the End of the Double-Blind Phase Number of Subjects Meeting PedACR70 Response Criteria at the End of the Double-Blind Phase Mean Change From Baseline in Physician's Global Assessment of Disease Activity at Week 48 of the Double-Blind Phase Mean Change From Baseline in Parent's/Patient's Global Assessment of Disease Activity at Week 48 of the Double-Blind Phase Mean Change From Baseline in C-Reactive Protein Levels at Week 48 of the Double-Blind Phase Number of Subjects Meeting PedACR30/50/70 Response Criteria at Baseline of the Open-Label Extension Body Surface Area Phase Number of Subjects Meeting PedACR30/50/70 Response Criteria at Week 56 of the Open-Label Extension Body Surface Area Phase Number of Subjects Meeting PedACR30/50/70 Response Criteria at Week 104 of the Open-Label Extension Body Surface Area Phase Number of Subjects Meeting PedACR30/50/70 Response Criteria at Baseline of the Open-Label Extension Fixed Dose Phase Number of Subjects Meeting PedACR30/50/70 Response Criteria at Week 48 of the Open-Label Extension Fixed Dose Phase Number of Subjects Meeting PedACR30/50/70 Response Criteria at Week 112 of the Open-Label Extension Fixed Dose Phase Number of Subjects Meeting PedACR30/50/70 Response Criteria at the Final Visit (up to 224 Weeks) of the Open-Label Extension Fixed Dose Phase
Detailed description:
The study design for this clinical trial was chosen to evaluate adalimumab in subjects who
were either methotrexate (MTX)-naive or had been withdrawn from MTX at least 2 weeks prior
to study drug administration (non-MTX stratum) or were inadequate responders to MTX and
continued MTX treatment (MTX stratum). The study consisted of 4 phases: a 16-week Open-label
Lead-in (OL LI), a 32-week Double-blind (DB) phase, an up to 136-week Open-label Extension
Body Surface Area (OLE BSA) phase, and an up to 224-week OLE Fixed Dose (FD) phase. All
subjects who met entry criteria were enrolled into one of the appropriate strata and
received adalimumab (plus concomitant MTX in the MTX stratum) in the 16 week OL LI phase of
the study. All subjects who responded to adalimumab during the OL LI phase were to be
enrolled in the DB phase of the study and randomized to receive adalimumab (plus concomitant
MTX in the MTX stratum) or placebo (plus concomitant MTX in the MTX stratum). Subjects in
the DB phase received either adalimumab (24 mg/m2 BSA up to a maximum of 40 mg total body
dose) or placebo subcutaneously (SC) administered every other week (eow). Adalimumab or
placebo was administered for an additional 32 weeks or until flare of disease (based on
PedACR30 response criteria = a worsening of 30% or more in 3 of the 6 response variables
(Parent's global assessment of subject's overall well-being by visual analog scale [VAS],
Physician's global assessment [PhGA] of subject's disease severity by VAS, number of active
joints [joints with swelling not due to deformity or joints with limitation of passive
motion (LOM)], pain, tenderness, or both, number of joints with LOM, Childhood Health
Assessment Questionnaire [CHAQ], and CRP levels), a minimum of 2 active joints, and no more
than 1 indicator improving by 30% or more), whichever occurred earlier. For subjects who did
not have a disease flare, the DB phase was completed at Week 48. Subjects who experienced
disease flare during the DB phase or subjects who completed 48 weeks of the study were given
the option to receive adalimumab for up to a minimum of 44 weeks (up to a maximum of 136
weeks) in the OLE BSA phase before being eligible to switch to the OLE FD phase. In this
phase, subjects received OL adalimumab (24 mg/m2 BSA up to a maximum of 40 mg total body
dose SC eow). All subjects who completed at least 44 weeks of OLE BSA treatment were given
the opportunity to continue into the OLE FD phase for up to 224 weeks of additional
adalimumab exposure. In this phase, subjects weighing less than 30 kg were treated with a
fixed dose of 20 mg of adalimumab SC eow. Subjects weighing 30 kg or more were treated with
a fixed dose of 40 mg of adalimumab SC eow.
Eligibility
Minimum age: 4 Years.
Maximum age: 17 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Subjects must have a diagnosis of polyarticular juvenile idiopathic arthritis (JIA)
age 4 to 17 by the American College of Rheumatology (ACR) criteria. Disease onset may
have been systemic, polyarticular, or pauciarticular. If the disease was systemic
onset, then the subjects must be free of any systemic JIA manifestations for at least
3 months before the time of qualification.
- At the time of study screening, the subject must have continuing active disease
defined as >= 5 swollen joints and >= 3 joints with limitation of motion (LOM). These
joints are not mutually exclusive.
- Subjects may be either naïve to MTX, inadequate responders to MTX, or intolerant to
MTX. Intolerance to MTX will be defined by the subject's physician. The MTX must be
maintained at a dose of at least 10 mg/m2 body surface area/week for a minimum of 3
months, prior to screening.
- Duration of disease is not limited, but must have been long enough for a subject to
have been given an adequate trial of nonsteroidal anti-inflammatory drugs (NSAIDs).
- Have not received other disease-modifying anti-rheumatic drugs (DMARDs) including
penicillamine, hydroxychloroquine, sulfasalazine, oral or injectable gold,
cyclosporin; or intravenous immunoglobulin (IV Ig); or cytotoxic agents, for at least
4 weeks prior to receiving 1st dose of study drug. Subjects currently on one or more
of these DMARDs must demonstrate active disease (defined above) prior to a minimum 4
weeks (28 days) washout of all DMARDs.
- Subjects who are refractory to MTX after 3 months of treatment must demonstrate
active disease (defined above) prior to enrollment in the open-label part of the
trial.
- Have not received an intra-articular glucocorticoid injection within 4 weeks (28
days) prior to enrollment into the study.
- Have good venous access and stable hematocrit >= 24%.
- All sexually active male and female study participants must be practicing adequate
contraception. Post-pubertal females must have a negative serum pregnancy test no
greater than 10 days prior to the first dose of study drug.
- Parent or guardian has voluntarily signed and dated an informed consent form,
approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC),
after the nature of the study has been explained and the subject's parent or legal
guardian has had the opportunity to ask questions.
Exclusion Criteria:
- Pregnant or nursing female.
- Functional class IV by ACR criteria.
- Laboratory parameters outside limits established in the protocol.
- Medical history, medical condition, or previous treatment not allowed by the
protocol.
Locations and Contacts
Site Reference ID/Investigator# 621, Ghent 9000, Belgium
Site Reference ID/Investigator# 2538, Leuven 3000, Belgium
Site Reference ID/Investigator# 518, Prague 2 128 50, Czech Republic
Site Reference ID/Investigator# 519, Prague 120 00, Czech Republic
Site Reference ID/Investigator# 45545, Marseille Cedex 20 13915, France
Site Reference ID/Investigator# 516, Paris 75015, France
Site Reference ID/Investigator# 627, Berlin 13353, Germany
Site Reference ID/Investigator# 625, Bremen D-28205, Germany
Site Ref # / Investigator 45522, Garmisch-Partenkirchen 82467, Germany
Site Reference ID/Investigator# 628, Halle (Saale) D-06120, Germany
Site Reference ID/Investigator# 622, Hamburg 22081, Germany
Site Reference ID/Investigator# 631, Genoa 16147, Italy
Site Reference ID/Investigator# 636, Milano 20122, Italy
Site Ref # / Investigator 45523, Kosice 004001, Slovakia
Site Reference ID/Investigator# 3425, Piestany 921 01, Slovakia
Site Reference ID/Investigator# 3713, Madrid 28034, Spain
Site Ref # / Investigator 45524, Birmingham, Alabama 35294-3300, United States
Site Reference ID/Investigator# 2235, Los Angeles, California 90027, United States
Site Reference ID/Investigator# 642, Stanford, California 94305, United States
Site Reference ID/Investigator# 638, Delray Beach, Florida 33406, United States
Site Ref # / Investigator 45543, St. Petersburg, Florida 33701, United States
Site Reference ID/Investigator# 640, Chicago, Illinois 60649, United States
Site Reference ID/Investigator# 644, Kansas City, Kansas 66160, United States
Site Reference ID/Investigator# 641, Minneapolis, Minnesota 55455, United States
Site Reference ID/Investigator# 645, Omaha, Nebraska 68131, United States
Site Reference ID/Investigator# 2501, Livingston, New Jersey 07039, United States
Site Ref # / Investigator 45542, New Hyde Park, New York 11040, United States
Site Ref # / Investigator 45544, Chapel Hill, North Carolina 27599-7220, United States
Site Reference ID/Investigator# 386, Columbus, Ohio 43205, United States
Site Ref # / Investigator 45525, Salt Lake City, Utah 84312-2206, United States
Site Reference ID/Investigator# 406, Norfolk, Virginia 23507, United States
Additional Information
Starting date: September 2002
Last updated: August 18, 2011
|